KDEV Karolinska Development AB

Prestigious publication confirms potential of technology used by Karolinska Development's portfolio company OssDsign

Prestigious publication confirms potential of technology used by Karolinska Development's portfolio company OssDsign
EN
14/10/2020

Underlying

KDEVKarolinska Development AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Karolinska Development AB

 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Development’s portfolio company AnaCardio completes patient...

Karolinska Development’s portfolio company AnaCardio completes patient recruitment in phase 2a study of its drug candidate AC01 STOCKHOLM, SWEDEN September 16, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed enrollment in the phase 2a part of its clinical study GOAL-HF1. The ongoing study evaluates AnaCardio’s drug candidate AC01 in patients with heart failure and reduced ejection fraction, with results expected by the end of the year. AnaCardio AB is a privately held Swedish clinical-stage biopharmaceutical company...

September 16, 2025 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Developments portföljbolag AnaCardio har slutfört rekryteri...

Karolinska Developments portföljbolag AnaCardio har slutfört rekryteringen i sin fas 2a-studie med läkemedelskandidaten AC01 STOCKHOLM, SVERIGE 16 september 2025 Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget AnaCardio har slutfört patientrekryteringen i fas 2a-delen av den kliniska studien GOAL-HF1. Den pågående studien utvärderar AnaCardios läkemedelskandidat AC01 i patienter med hjärtsvikt och försämrad pumpfunktion, med förväntade resultat i slutet av innevarande år. AnaCardio är ett privatägt, svenskt biopharma-bolag i klinisk fas som utvecklar ny...

September 16, 2025 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Development’s portfolio company Umecrine Cognition publishe...

Karolinska Development’s portfolio company Umecrine Cognition publishes data showing sustained effect of golexanolone in a Parkinson’s disease model STOCKHOLM – September 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented data showing that its drug candidate golexanolone provides sustained reversal of neuroinflammation in a Parkinson's disease model. The data, published in the scientific journal Frontiers in Immunology, support a key mechanism for golexanolone in alleviating symptoms of Parkinson’s disease,...

September 4, 2025 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Developments portföljbolag Umecrine Cognition publicerar da...

Karolinska Developments portföljbolag Umecrine Cognition publicerar data som visar på ihållande effekt av golexanolon i preklinisk Parkinsonmodell STOCKHOLM, 4 september 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition presenterar data som visar att läkemedelskandidaten golexanolon ger ihållande reversering av neuroinflammation i en sjukdomsmodell av Parkinson. Resultaten, som publiceras i den vetenskapliga tidskriften Frontiers in Immunology, belyser verkningsmekanismen för golexanolon vid lindring av symtomen av Parkinsons sjukdom, v...

September 4, 2025 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Interim Report - January-June 2025

Interim Report - January-June 2025 STOCKHOLM – 29 August 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-June 2025. The full report is available on the Company's website. “We have a clear strategy and a stable scientific foundation for all of the projects in our investment portfolio, and will navigate these choppy market waters by keeping our focus on patient benefit”, says Viktor Drvota, CEO, Karolinska Development. Significant events during the second quarter The portfolio company Umecrine Cognition presented recent preclinical da...

August 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch